Related Experiment Video
Updated: Jul 14, 2026
11:16
A Novel Procedure for Evaluating the Reinforcing Properties of Tastants in Laboratory Rats: Operant Intraoral Self-administration
Published on: February 6, 2014
[CHANGING THE PHYSIOLOGICAL PROPERTIES OF ORAL LIQUID FOR OBESITY]
Likars'Ka Sprava
|August 6, 2016
Summary
Oral fluid homeostasis monitoring offers a noninvasive method for assessing overall health and early oral disease detection. Obesity significantly alters key oral fluid properties like pH, flow rate, and viscosity.
Area of Science:
- Biomedical Science
- Oral Biology
- Physiology
Context:
- Oral fluid analysis provides a noninvasive window into systemic health.
- Understanding oral fluid homeostasis is crucial for early disease detection.
- Obesity is a growing global health concern with systemic implications.
Purpose:
- To investigate the impact of obesity on the physiological properties of oral fluid.
- To establish correlations between obesity and changes in oral fluid pH, salivary flow rate, and viscosity.
Summary:
- This study examined alterations in oral fluid pH, salivary flow rate, and viscosity in individuals with obesity.
- Findings indicate significant deviations in these physiological parameters compared to non-obese controls.
- These changes highlight potential oral health implications associated with obesity.
Impact:
- Provides baseline data for noninvasive oral fluid diagnostics in obesity.
- Suggests potential mechanisms linking obesity to oral health issues.
- Informs future research on salivary biomarkers for metabolic health.
Related Concept Videos
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...